MX2020006355A - Pirrolidinamidas ii sustituidas. - Google Patents

Pirrolidinamidas ii sustituidas.

Info

Publication number
MX2020006355A
MX2020006355A MX2020006355A MX2020006355A MX2020006355A MX 2020006355 A MX2020006355 A MX 2020006355A MX 2020006355 A MX2020006355 A MX 2020006355A MX 2020006355 A MX2020006355 A MX 2020006355A MX 2020006355 A MX2020006355 A MX 2020006355A
Authority
MX
Mexico
Prior art keywords
pyrrolidinamides
substituted
glucocorticoid receptor
prophylaxis
disorders
Prior art date
Application number
MX2020006355A
Other languages
English (en)
Inventor
Jo Alen
Florian Jakob
Sebastian Krüger
Markus Schade
Daniela Friebe
Stephanie Hennen
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2020006355A publication Critical patent/MX2020006355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invención se refiere a compuestos de acuerdo con la fórmula general (I), (ver formula) que actúan como moduladores del receptor de glucocorticoides y se pueden utilizar en el tratamiento y/o la profilaxis de trastornos que están al menos parcialmente mediados por el receptor de glucocorticoides.
MX2020006355A 2017-12-18 2018-12-18 Pirrolidinamidas ii sustituidas. MX2020006355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17208180 2017-12-18
PCT/EP2018/085390 WO2019121611A1 (en) 2017-12-18 2018-12-18 Substituted pyrrolidine amides ii

Publications (1)

Publication Number Publication Date
MX2020006355A true MX2020006355A (es) 2020-08-17

Family

ID=60673848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006355A MX2020006355A (es) 2017-12-18 2018-12-18 Pirrolidinamidas ii sustituidas.

Country Status (14)

Country Link
US (2) US20190185470A1 (es)
EP (1) EP3728233B1 (es)
JP (1) JP2021506965A (es)
CN (1) CN111491931A (es)
AR (1) AR113968A1 (es)
AU (1) AU2018387747A1 (es)
BR (1) BR112020012221A2 (es)
CA (1) CA3085879A1 (es)
EA (1) EA202091428A1 (es)
ES (1) ES2920359T3 (es)
IL (1) IL275375A (es)
MX (1) MX2020006355A (es)
TW (1) TW201927769A (es)
WO (1) WO2019121611A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201927770A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉ
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
WO2020254551A1 (en) * 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides iv
AU2021296163B2 (en) 2020-06-22 2024-07-04 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor
KR20240125035A (ko) * 2021-12-21 2024-08-19 코어셉트 쎄라퓨틱스 인코포레이티드 이환 인다졸 글루코코르티코이드 수용체 길항제
IL313663A (en) * 2021-12-21 2024-08-01 Corcept Therapeutics Inc Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535884A (ja) * 2005-04-14 2008-09-04 グラクソ グループ リミテッド グルココルチコイド受容体リガンドとしてのインダゾール
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
JP2009084273A (ja) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd １，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体からなるグルココルチコイド受容体アゴニスト
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
ES2751640T3 (es) 2014-09-26 2020-04-01 Astrazeneca Ab Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y uso como moduladores de SGRM
CN107922356A (zh) 2015-08-25 2018-04-17 参天制药株式会社 [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐
EP3347353B1 (en) * 2015-09-11 2019-07-17 Boehringer Ingelheim International GmbH Pyrazolyl-substituted heteroaryls and their use as medicaments
TW201927770A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉ

Also Published As

Publication number Publication date
US12344605B2 (en) 2025-07-01
EA202091428A1 (ru) 2020-10-27
IL275375A (en) 2020-07-30
AR113968A1 (es) 2020-07-01
US20190185470A1 (en) 2019-06-20
JP2021506965A (ja) 2021-02-22
TW201927769A (zh) 2019-07-16
BR112020012221A2 (pt) 2020-11-24
AU2018387747A1 (en) 2020-08-06
CA3085879A1 (en) 2019-06-27
US20220127264A1 (en) 2022-04-28
WO2019121611A1 (en) 2019-06-27
EP3728233B1 (en) 2022-04-20
ES2920359T3 (es) 2022-08-03
CN111491931A (zh) 2020-08-04
EP3728233A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
ECSP21051067A (es) Amidas de pirrolidina III sustituidas
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2019007881A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
ECSP21003718A (es) Derivados de triazolquinoxalina adicionalmente sustituidos
CO2019007882A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX2020006348A (es) Pirrolidinamidas i sustituidas.
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
MX2021000762A (es) Derivados de triazoloquinoxalina sustituida.
MX2017014128A (es) 2-tiopirimidinonas.
TR201401753A2 (tr) Nekroz tedavisine yönelik bir kompozisyon.